{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:47:53Z","timestamp":1785451673576,"version":"3.56.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00417-023-06083-4","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T06:45:01Z","timestamp":1683787501000},"page":"3355-3367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Topical diquafosol versus hyaluronic acid for the treatment of dry eye disease: a meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"261","author":[{"given":"Xiaonan","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9250-9546","authenticated-orcid":false,"given":"Chi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"6083_CR1","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1159\/000525696000525696","volume":"65","author":"Y Cai","year":"2022","unstructured":"Cai Y, Wei J, Zhou J, Zou W (2022) Prevalence and incidence of dry eye disease in Asia: a systematic review and meta-analysis. Ophthalmic Res 65:647\u2013658. https:\/\/doi.org\/10.1159\/000525696000525696","journal-title":"Ophthalmic Res"},{"key":"6083_CR2","doi-asserted-by":"publisher","first-page":"e0271267","DOI":"10.1371\/journal.pone.0271267","volume":"17","author":"L Qian","year":"2022","unstructured":"Qian L, Wei W (2022) Identified risk factors for dry eye syndrome: a systematic review and meta-analysis. PloS One 17:e0271267. https:\/\/doi.org\/10.1371\/journal.pone.0271267","journal-title":"PloS One"},{"key":"6083_CR3","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/aos.15150AOS15150","volume":"100","author":"K Fjaervoll","year":"2022","unstructured":"Fjaervoll K, Fjaervoll H, Magno M, Noland ST, Dartt DA, Vehof J, Utheim TP (2022) Review on the possible pathophysiological mechanisms underlying visual display terminal-associated dry eye disease. Acta Ophthalmol 100:861\u2013877. https:\/\/doi.org\/10.1111\/aos.15150AOS15150","journal-title":"Acta Ophthalmol"},{"key":"6083_CR4","doi-asserted-by":"publisher","unstructured":"Sekhon AS, He B, Iovieno A, Yeung SN (2021) Pathophysiology of corneal endothelial cell loss in dry eye disease and other inflammatory ocular disorders. Ocul Immunol Inflamm 1-11. https:\/\/doi.org\/10.1080\/09273948.2021.1980808","DOI":"10.1080\/09273948.2021.1980808"},{"key":"6083_CR5","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1177\/11206721211060963","volume":"32","author":"A Basilious","year":"2022","unstructured":"Basilious A, Xu CY, Malvankar-Mehta MS (2022) Dry eye disease and psychiatric disorders: a systematic review and meta-analysis. Eur J Ophthalmol 32:1872\u20131889. https:\/\/doi.org\/10.1177\/11206721211060963","journal-title":"Eur J Ophthalmol"},{"key":"6083_CR6","doi-asserted-by":"publisher","first-page":"P286","DOI":"10.1016\/j.ophtha.2018.10.023","volume":"126","author":"EK Akpek","year":"2019","unstructured":"Akpek EK, Amescua G, Farid M, Garcia-Ferrer FJ, Lin A, Rhee MK, Varu DM, Musch DC, Dunn SP, Mah FS (2019) American Academy of Ophthalmology Preferred Practice Pattern Cornea and External Disease Panel. Ophthalmology 126:P286\u2013P334. https:\/\/doi.org\/10.1016\/j.ophtha.2018.10.023","journal-title":"Ophthalmology"},{"key":"6083_CR7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/02713683.2022.2039205","volume":"47","author":"M Rolando","year":"2022","unstructured":"Rolando M, Merayo-Lloves J (2022) Management strategies for evaporative dry eye disease and future perspective. Curr Eye Res 47:813\u2013823. https:\/\/doi.org\/10.1080\/02713683.2022.2039205","journal-title":"Curr Eye Res"},{"key":"6083_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/07853890.2022.2157477","volume":"55","author":"J Sheppard","year":"2023","unstructured":"Sheppard J, Shen Lee B, Periman LM (2023) Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists. Ann Med 55:241\u2013252. https:\/\/doi.org\/10.1080\/07853890.2022.2157477","journal-title":"Ann Med"},{"key":"6083_CR9","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.3390\/ijerph18052383","volume":"18","author":"YJ Yang","year":"2021","unstructured":"Yang YJ, Lee WY, Kim YJ, Hong YP (2021) A meta-analysis of the efficacy of hyaluronic acid eye drops for the treatment of dry eye syndrome. Int J Environ Res Public Health 18:2383. https:\/\/doi.org\/10.3390\/ijerph18052383","journal-title":"Int J Environ Res Public Health"},{"key":"6083_CR10","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/aos.15159AOS15159","volume":"100","author":"L Hynnekleiv","year":"2022","unstructured":"Hynnekleiv L, Magno M, Vernhardsdottir RR, Moschowits E, Tonseth KA, Dartt DA, Vehof J, Utheim TP (2022) Hyaluronic acid in the treatment of dry eye disease. Acta Ophthalmol 100:844\u2013860. https:\/\/doi.org\/10.1111\/aos.15159AOS15159","journal-title":"Acta Ophthalmol"},{"key":"6083_CR11","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s40265-015-0409-7","volume":"75","author":"GM Keating","year":"2015","unstructured":"Keating GM (2015) Diquafosol ophthalmic solution 3 %: a review of its use in dry eye. Drugs 75:911\u2013922. https:\/\/doi.org\/10.1007\/s40265-015-0409-7","journal-title":"Drugs"},{"key":"6083_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s12325-012-0033-9","volume":"29","author":"M Nakamura","year":"2012","unstructured":"Nakamura M, Imanaka T, Sakamoto A (2012) Diquafosol ophthalmic solution for dry eye treatment. Adv Ther 29:579\u2013589. https:\/\/doi.org\/10.1007\/s12325-012-0033-9","journal-title":"Adv Ther"},{"key":"6083_CR13","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/eye.2012.166eye2012166","volume":"26","author":"K Kamiya","year":"2012","unstructured":"Kamiya K, Nakanishi M, Ishii R, Kobashi H, Igarashi A, Sato N, Shimizu K (2012) Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study. Eye (Lond) 26:1363\u20131368. https:\/\/doi.org\/10.1038\/eye.2012.166eye2012166","journal-title":"Eye (Lond)"},{"key":"6083_CR14","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1136\/bjophthalmol-2011-301448","volume":"96","author":"E Takamura","year":"2012","unstructured":"Takamura E, Tsubota K, Watanabe H, Ohashi Y (2012) A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol 96:1310\u20131315. https:\/\/doi.org\/10.1136\/bjophthalmol-2011-301448","journal-title":"Br J Ophthalmol"},{"key":"6083_CR15","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1097\/ICO.0000000000000213","volume":"33","author":"HS Hwang","year":"2014","unstructured":"Hwang HS, Sung YM, Lee WS, Kim EC (2014) Additive effect of preservative-free sodium hyaluronate 0.1% in treatment of dry eye syndrome with diquafosol 3% eye drops. Cornea 33:935\u2013941. https:\/\/doi.org\/10.1097\/ICO.0000000000000213","journal-title":"Cornea"},{"issue":"616-622","key":"6083_CR16","doi-asserted-by":"publisher","first-page":"e611","DOI":"10.1016\/j.ajo.2013.11.017","volume":"157","author":"I Toda","year":"2014","unstructured":"Toda I, Ide T, Fukumoto T, Ichihashi Y, Tsubota K (2014) Combination therapy with diquafosol tetrasodium and sodium hyaluronate in patients with dry eye after laser in situ keratomileusis. Am J Ophthalmol 157(616-622):e611. https:\/\/doi.org\/10.1016\/j.ajo.2013.11.017","journal-title":"Am J Ophthalmol"},{"key":"6083_CR17","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1136\/bjophthalmol-2014-306084","volume":"99","author":"L Gong","year":"2015","unstructured":"Gong L, Sun X, Ma Z, Wang Q, Xu X, Chen X, Shao Y, Yao K, Tang L, Gu Y, Yuan H, Chua WH, Chuan JC, Tong L (2015) A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore. Br J Ophthalmol 99:903\u2013908. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-306084","journal-title":"Br J Ophthalmol"},{"issue":"122-131","key":"6083_CR18","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1016\/j.ajo.2015.12.002","volume":"163","author":"DH Park","year":"2016","unstructured":"Park DH, Chung JK, Seo DR, Lee SJ (2016) Clinical effects and safety of 3% diquafosol ophthalmic solution for patients with dry eye after cataract surgery: a randomized controlled trial. Am J Ophthalmol 163(122-131):e122. https:\/\/doi.org\/10.1016\/j.ajo.2015.12.002","journal-title":"Am J Ophthalmol"},{"key":"6083_CR19","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1007\/s10792-017-0693-1","volume":"38","author":"L Cui","year":"2018","unstructured":"Cui L, Li Y, Lee HS, Yang JM, Choi W, Yoon KC (2018) Effect of diquafosol tetrasodium 3% on the conjunctival surface and clinical findings after cataract surgery in patients with dry eye. Int Ophthalmol 38:2021\u20132030. https:\/\/doi.org\/10.1007\/s10792-017-0693-1","journal-title":"Int Ophthalmol"},{"key":"6083_CR20","doi-asserted-by":"publisher","first-page":"12659","DOI":"10.1038\/s41598-019-49159-01265910","volume":"9","author":"I Jun","year":"2019","unstructured":"Jun I, Choi S, Lee GY, Choi YJ, Lee HK, Kim EK, Seo KY, Kim TI (2019) Effects of preservative-free 3% diquafosol in patients with pre-existing dry eye disease after cataract surgery: a randomized clinical trial. Sci Rep 9:12659. https:\/\/doi.org\/10.1038\/s41598-019-49159-01265910","journal-title":"Sci Rep"},{"key":"6083_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1089\/jop.2021.0083","volume":"38","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Zhang H, Qin G, Wu Y, Song Y, Yang L, Yu S, He X, Moore JE, Moutari S, Palme C, Xu L, He W, Pazo EE (2022) Impact of diquafosol ophthalmic solution on tear film and dry eye symptom in type 2 diabetic dry eye: a pilot study. J Ocul Pharmacol Ther 38:133\u2013140. https:\/\/doi.org\/10.1089\/jop.2021.0083","journal-title":"J Ocul Pharmacol Ther"},{"key":"6083_CR22","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hrobjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"6083_CR23","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hrobjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S et al (2021) PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 372:n160. https:\/\/doi.org\/10.1136\/bmj.n160","journal-title":"BMJ"},{"key":"6083_CR24","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, Welch V (2021) Cochrane Handbook for Systematic Reviews of Interventions version 6.2. The Cochrane Collaboration. www.training.cochrane.org\/handbook"},{"key":"6083_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"6083_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"key":"6083_CR27","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1097\/ICO.0000000000000429","volume":"34","author":"D Wu","year":"2015","unstructured":"Wu D, Chen WQ, Li R, Wang Y (2015) Efficacy and safety of topical diquafosol ophthalmic solution for treatment of dry eye: a systematic review of randomized clinical trials. Cornea 34:644\u2013650. https:\/\/doi.org\/10.1097\/ICO.0000000000000429","journal-title":"Cornea"},{"key":"6083_CR28","doi-asserted-by":"publisher","first-page":"e8174","DOI":"10.1097\/md.0000000000008174","volume":"96","author":"X Zhao","year":"2017","unstructured":"Zhao X, Xia S, Chen Y (2017) Comparison of the efficacy between topical diquafosol and artificial tears in the treatment of dry eye following cataract surgery: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 96:e8174. https:\/\/doi.org\/10.1097\/md.0000000000008174","journal-title":"Medicine (Baltimore)"},{"key":"6083_CR29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1159\/000492896000492896[pii]","volume":"61","author":"K Nam","year":"2019","unstructured":"Nam K, Kim HJ, Yoo A (2019) Efficacy and safety of topical 3% diquafosol ophthalmic solution for the treatment of multifactorial dry eye disease: meta-analysis of randomized clinical trials. Ophthalmic Res 61:188\u2013198. https:\/\/doi.org\/10.1159\/000492896000492896[pii]","journal-title":"Ophthalmic Res"},{"key":"6083_CR30","first-page":"929","volume":"20","author":"T Kojima","year":"2014","unstructured":"Kojima T, Dogru M, Ibrahim OM, Nagata T, Higa K, Shimizu T, Shirasawa T, Satake Y, Shimazaki S, Shimazaki J, Tsubota K (2014) The effects of 3% diquafosol sodium application on the tear functions and ocular surface of the Cu,Zn-superoxide dismutase-1 (Sod1)-knockout mice. Mol Vis 20:929\u2013938","journal-title":"Mol Vis"},{"key":"6083_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.exer.2015.10.013","volume":"143","author":"YS Byun","year":"2016","unstructured":"Byun YS, Yoo YS, Kwon JY, Joo JS, Lim SA, Whang WJ, Mok JW, Choi JS, Joo CK (2016) Diquafosol promotes corneal epithelial healing via intracellular calcium-mediated ERK activation. Exp Eye Res 143:89\u201397. https:\/\/doi.org\/10.1016\/j.exer.2015.10.013","journal-title":"Exp Eye Res"},{"key":"6083_CR32","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00417-018-3932-x10","volume":"256","author":"K Ikeda","year":"2018","unstructured":"Ikeda K, Simsek C, Kojima T, Higa K, Kawashima M, Dogru M, Shimizu T, Tsubota K, Shimazaki J (2018) The effects of 3% diquafosol sodium eye drop application on meibomian gland and ocular surface alterations in the Cu, Zn-superoxide dismutase-1 (Sod1) knockout mice. Graefes Arch Clin Exp Ophthalmol 256:739\u2013750. https:\/\/doi.org\/10.1007\/s00417-018-3932-x10","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6083_CR33","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.1167\/iovs.17-229252711318","volume":"59","author":"JH Park","year":"2018","unstructured":"Park JH, Moon SH, Kang DH, Um HJ, Kang SS, Kim JY, Tchah H (2018) Diquafosol sodium inhibits apoptosis and inflammation of corneal epithelial cells via activation of Erk1\/2 and RSK: in vitro and in vivo dry eye model. Invest Ophthalmol Vis Sci 59:5108\u20135115. https:\/\/doi.org\/10.1167\/iovs.17-229252711318","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6083_CR34","doi-asserted-by":"publisher","first-page":"6989","DOI":"10.1038\/s41598-021-86433-66989","volume":"11","author":"KI Endo","year":"2021","unstructured":"Endo KI, Sakamoto A, Fujisawa K (2021) Diquafosol tetrasodium elicits total cholesterol release from rabbit meibomian gland cells via P2Y(2) purinergic receptor signalling. Sci Rep 11:6989. https:\/\/doi.org\/10.1038\/s41598-021-86433-66989","journal-title":"Sci Rep"},{"key":"6083_CR35","doi-asserted-by":"publisher","first-page":"136939","DOI":"10.1016\/j.neulet.2022.136939","volume":"792","author":"A Katagiri","year":"2023","unstructured":"Katagiri A, Tsubota K, Mikuzuki L, Nakamura S, Toyofuku A, Kato T, Bereiter DA, Iwata K (2023) Diquafosol sodium reduces neuronal activity in trigeminal subnucleus caudalis in a rat model of chronic dry eye disease. Neurosci Lett 792:136939. https:\/\/doi.org\/10.1016\/j.neulet.2022.136939","journal-title":"Neurosci Lett"},{"key":"6083_CR36","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1016\/j.ophtha.2012.04.010","volume":"119","author":"Y Matsumoto","year":"2012","unstructured":"Matsumoto Y, Ohashi Y, Watanabe H, Tsubota K (2012) Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial. Ophthalmology 119:1954\u20131960. https:\/\/doi.org\/10.1016\/j.ophtha.2012.04.010","journal-title":"Ophthalmology"},{"key":"6083_CR37","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2147\/OPTH.S131384opth-11-631","volume":"11","author":"D Gross","year":"2017","unstructured":"Gross D, Childs M, Piaton JM (2017) Comparison of 0.2% and 0.18% hyaluronate eye drops in patients with moderate to severe dry eye with keratitis or keratoconjunctivitis. Clin Ophthalmol 11:631\u2013638. https:\/\/doi.org\/10.2147\/OPTH.S131384opth-11-631","journal-title":"Clin Ophthalmol"},{"key":"6083_CR38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1089\/jop.2016.0086","volume":"33","author":"Y Park","year":"2017","unstructured":"Park Y, Song JS, Choi CY, Yoon KC, Lee HK, Kim HS (2017) A randomized multicenter study comparing 0.1%, 0.15%, and 0.3% sodium hyaluronate with 0.05% cyclosporine in the treatment of dry eye. J Ocul Pharmacol Ther 33:66\u201372. https:\/\/doi.org\/10.1089\/jop.2016.0086","journal-title":"J Ocul Pharmacol Ther"},{"key":"6083_CR39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1167\/tvst.8.6.22TVST-19-1425","volume":"8","author":"P Aragona","year":"2019","unstructured":"Aragona P, Simmons PA, Wang H, Wang T (2019) Physicochemical properties of hyaluronic acid-based lubricant eye drops. Transl Vis Sci Technol 8:2. https:\/\/doi.org\/10.1167\/tvst.8.6.22TVST-19-1425","journal-title":"Transl Vis Sci Technol"},{"key":"6083_CR40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1167\/tvst.9.5.2525TVST-19-1699","volume":"9","author":"EJ Berg","year":"2020","unstructured":"Berg EJ, Ying GS, Maguire MG, Sheffield PE, Szczotka-Flynn LB, Asbell PA, Shen JF (2020) Climatic and environmental correlates of dry eye disease severity: a report from the Dry Eye Assessment and Management (DREAM) Study. Transl Vis Sci Technol 9:25. https:\/\/doi.org\/10.1167\/tvst.9.5.2525TVST-19-1699","journal-title":"Transl Vis Sci Technol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06083-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-023-06083-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06083-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T04:30:45Z","timestamp":1700800245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-023-06083-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["6083"],"URL":"https:\/\/doi.org\/10.1007\/s00417-023-06083-4","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]},"assertion":[{"value":"9 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study does not contain any studies with human participants or animals performed by any of the authors. For this type of study, formal consent is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}